Sorafenib inhibits ovarian cancer cell proliferation and mobility and induces radiosensitivity by targeting the tumor cell epithelial mesenchymal transition

Sorafenib, a pan-protein kinase inhibitor, inhibits the activity of various kinases (like vascular endothelial growth factor, platelet-derived growth factor, and rapidly accelerated fibrosarcoma) and clinically has been used to treat different human cancers. This study investigated its antitumor activity in ovarian cancer and the underlying molecular events. To achieve that, ovarian cancer SKOV3 cells were treated with or without sorafenib (10 mu M), transforming growth factor (TGF)-beta 1 (10 ng/mL), sorafenib (10 mu M) + TGF-beta 1 (10 ng/mL), and TGF-beta 1 (10 ng/mL) + Ly2157299 (5 mu M), followed by 8-Gy radiation. The cells were then subjected to cell viability, wound healing, Transwell, caspase-3 activity, and western blot assays. TGF-beta 1 treatment enhanced ovarian cancer cell epithelial-mesenchymal transition (EMT), whereas sorafenib and a selective TGF-beta 1 inhibitor Ly2157299 reversed tumor cell EMT, invasion, and expression of EMT markers (E-cadherin and vimentin). Sorafenib and Ly2157299 treatment also significantly reduced the tumor cell viability. Furthermore, both sorafenib and Ly2157299 significantly enhanced ovarian cancer cell radiosensitivity, as assessed by a caspase-3 activity assay. In conclusion, sorafenib inhibited ovarian cancer cell proliferation and mobility and induced tumor cell radiosensitivity. Molecularly, sorafenib could inhibit the TGF-beta 1-mediated EMT. Future studies will assess sorafenib anti-ovarian cancer activity plus TGF-beta 1 inhibitors in ovarian cancer in vivo.